AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 83 min read$CRSP

Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (CRSP) reported $76M in Q2 2026 revenue from Casgevy, up 78% sequentially and 151% YoY. The company has a strong pipeline, including CTX310 for cardiovascular disease and Zugo-cel for autoimmune diseases. With $2.36B in cash and a $5.4B market cap, CRISPR has financial flexibility to advance multiple programs. Success in these areas could significantly increase its valuation by 2031, though risks remain.

Original reporting
yahoo.com
Published Sep 8, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 4:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Where Will CRISPR Therapeutics Stock Be in 5 Years? — source image
Source · yahoo.com
Decision brief

The 30-second read

$CRSPBullishMed
01

Why it matters

The disclosed phase‑1 results for CTX310 provide the first quantitative efficacy signal for an in‑vivo CRISPR therapy targeting lipid disorders.

02

Market read

New clinical data and revenue figures could influence investor sentiment toward CRISPR and the broader gene‑editing space.

03

What to watch

Cash runway is strong, but dilution risk and regulatory scrutiny of in‑vivo editing remain concerns.

Relevance 8/10Novelty 9/10Timing: recent Q2 2026 revenue and fresh phase‑1 data released Sep 2026

Background

CRISPR Therapeutics has one FDA‑approved product (Casgevy) and is expanding its pipeline with multiple gene‑editing programs.

Company-level read

Ticker impact

$CRSPBullishMedium confidence
Context

CRISPR Therapeutics disclosed phase 1 data for CTX310 (53% LDL reduction) and Q2 2026 revenue of $76M from its approved product Casgevy.

Expected impact

Potential modest upside in the next 3‑6 months if data is validated; high volatility expected.

Evidence & confidence

Phase‑1 results are encouraging but still early; market typically reacts cautiously to pre‑clinical milestones.

Market effects

Sector

Strengthens the gene‑editing sector outlook, highlighting potential for cardiovascular therapies.

Regional

U.S. biotech investors may increase exposure to CRISPR and related gene‑editing firms.

Global

Shows progress of CRISPR technology worldwide, may influence global biotech funding trends.

Counterpoint

What could challenge this read

Early‑stage data may be over‑hyped; failure in later trials could sharply depress the stock.

Key entities

  • company
    CRISPR Therapeutics

    NASDAQ‑listed gene‑editing biotech (ticker CRSP).

  • partner
    Vertex Pharmaceuticals

    Co‑developer and commercial partner for Casgevy.

Read at source← All news

Related articles

SEP 8
$CRSPMedAI 8/10

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics (CRSP) shares rose 19% in August following its Q2 earnings report. Sales of its blood disorder treatment Casgevy increased 78% to $76M, and the FDA expanded its approval. Revenue reached $10.2M, up from $892K a year ago, with a net loss of $91.5M. Analysts expected lower revenue and a larger loss. The company is developing treatments for hypertension and other disorders.

yahoo.com3 min
AUG 30
$CRSPMedAI 8/10

CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data

CRISPR Therapeutics (CRSP) stock is down 52.7% over 5 years, despite recent gains. The company presented Phase 1a data for CTX310, which may boost confidence in its drug pipeline. However, the stock is considered overvalued on market multiples, trading at a P/B of 3.2x, above the biotech industry average. Investors are paying a premium for its pipeline potential, but clinical and regulatory risks remain significant.

simplywall.st3 min
AUG 28
$CRSPMedAI 8/10

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

CRISPR Therapeutics (CRSP) presented Phase 1a data for CTX310® at ESC Congress 2026, showing mean reductions of 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL at the highest dose. The therapy was well tolerated with no serious adverse events. Data was also published in The New England Journal of Medicine. The company is advancing CTX310 in a Phase 1b trial and expects to provide an update in the second half of 2026.

globenewswire.com2 min
AUG 4
$CRSPMed

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics (CRSP) reported a Q2 2026 loss of 94 cents per share, narrower than the Zacks estimate of a $1.10 loss. Revenue rose to $10.2 million, above the $7 million estimate. Vertex’s Casgevy sales were $76 million in Q2. CRSP ended June with $2.36 billion cash and said multiple pipeline updates are expected in H2 2026.

zacks.com6 min
AUG 3
$CRSPMed

CRISPR Therapeutics reports $91.2 million second quarter net loss

CRISPR Therapeutics (CRSP) reported Q2 2026 total revenue of $10.2M and a net loss of $91.2M for the quarter ended June 30. Cash, cash equivalents and marketable securities were $2.36B vs $1.98B at end-2025. CASGEVY revenue was $76M, up 78% QoQ and 151% YoY. The company cited FDA approval for children as young as 2 and began Phase 1 trials for CTX340 and CTX460.

quiverquant.com4 min